| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gilda Varricchi | Q89613143 |
| Matteo Ferrando | Q55094094 | ||
| Giorgio Walter Canonica | Q56380976 | ||
| Diego Bagnasco | Q60981423 | ||
| Giovanni Passalacqua | Q61949008 | ||
| P2093 | author name string | Stefano Bernardi | |
| Alice Bragantini | |||
| P2860 | cites work | Ecallantide for the treatment of acute attacks in hereditary angioedema | Q84984709 |
| Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study | Q86175453 | ||
| Mutational spectrum of the c1 inhibitor gene in a cohort of Italian patients with hereditary angioedema: description of nine novel mutations | Q87152066 | ||
| Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema | Q87285114 | ||
| Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis | Q24187980 | ||
| Allergen Immunotherapy (AIT): a prototype of Precision Medicine | Q26776512 | ||
| Biomarkers and severe asthma: a critical appraisal | Q26782718 | ||
| Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group | Q27009012 | ||
| Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs | Q28067081 | ||
| Biologics in asthma--the next step toward personalized treatment | Q28085614 | ||
| Paul Ehrlich's magic bullets | Q28249801 | ||
| Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys | Q29615415 | ||
| Canadian hereditary angioedema guideline | Q30596332 | ||
| Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. | Q34035726 | ||
| Hereditary angioedema | Q71073989 | ||
| Exhaled nitric oxide levels correlate with measures of disease control in asthma | Q73076824 | ||
| Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema | Q73288257 | ||
| Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis | Q77633152 | ||
| Pattern of hospitalizations for angioedema in New York between 1990 and 2003 | Q81150267 | ||
| Hereditary angio-oedema | Q83392014 | ||
| Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome | Q84332714 | ||
| Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma | Q34069800 | ||
| Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma | Q34098997 | ||
| A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria | Q34200855 | ||
| Lebrikizumab treatment in adults with asthma | Q34205683 | ||
| Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry | Q34324456 | ||
| Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy | Q34354169 | ||
| The trials and tribulations of IL-5, eosinophils, and allergic asthma | Q34394617 | ||
| Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production | Q34427691 | ||
| Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents | Q34627140 | ||
| Treatment of patients with the hypereosinophilic syndrome with mepolizumab | Q34762186 | ||
| Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects | Q34782224 | ||
| Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children | Q34979344 | ||
| Long-term benefits of omalizumab in a patient with severe non-allergic asthma | Q35078215 | ||
| An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications | Q35534747 | ||
| ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE | Q35570649 | ||
| Omalizumab for asthma | Q36514489 | ||
| Asthma treatment: 'magic bullets which seek their own targets'. | Q36825045 | ||
| Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation | Q37029492 | ||
| Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe | Q37114784 | ||
| Biomarkers in asthma | Q37349068 | ||
| Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study | Q37371731 | ||
| IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. | Q37474764 | ||
| Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy | Q37604549 | ||
| Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab | Q37607069 | ||
| Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma | Q37778201 | ||
| New insights into hereditary angio-oedema: Molecular diagnosis and therapy | Q37778847 | ||
| Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome | Q37833778 | ||
| Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence | Q38156139 | ||
| CCL11 as a potential diagnostic marker for asthma? | Q38209386 | ||
| Clinical efficacy of anti-IgE therapy for eosinophilic otitis media | Q50429705 | ||
| Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. | Q50551924 | ||
| Home Therapy with Plasma-Derived C1 Inhibitor: A Strategy to Improve Clinical Outcomes and Costs in Hereditary Angioedema. | Q50559152 | ||
| Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. | Q51026334 | ||
| Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. | Q51699006 | ||
| Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. | Q53310678 | ||
| Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. | Q53583932 | ||
| Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media | Q58299909 | ||
| MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function | Q60632052 | ||
| The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults | Q63352971 | ||
| The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria | Q38221816 | ||
| Interaction of IgE with its high-affinity receptor. Structural basis and requirements for effective cross-linking. | Q38252330 | ||
| FeNO as biomarker for asthma phenotyping and management. | Q38308703 | ||
| The relationship between allergen immunotherapy and omalizumab for treating asthma. | Q38314276 | ||
| Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care | Q38348052 | ||
| Critical appraisal of androgen use in hereditary angioedema: a systematic review | Q38364383 | ||
| Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey | Q38405038 | ||
| Role of biologics in intractable urticaria | Q38450662 | ||
| Angioedema induced by cardiovascular drugs: new players join old friends | Q38539515 | ||
| New Insights into Eosinophilic Otitis Media | Q38627482 | ||
| Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? | Q38632790 | ||
| Biosimilars in allergic diseases | Q38643541 | ||
| A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. | Q38956459 | ||
| Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. | Q39194170 | ||
| Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma | Q39236427 | ||
| The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. | Q39309234 | ||
| Exhaled breath condensate: methodological recommendations and unresolved questions. | Q40392502 | ||
| AIT (allergen immunotherapy): a model for the "precision medicine". | Q41134553 | ||
| Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials | Q41452053 | ||
| Periostin promotes chronic allergic inflammation in response to Th2 cytokines. | Q41926592 | ||
| Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma | Q43701894 | ||
| Airway inflammation is present during clinical remission of atopic asthma. | Q43819606 | ||
| Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study | Q43841288 | ||
| Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines | Q43981058 | ||
| Usefulness of omalizumab in ten patients with severe occupational asthma | Q43995376 | ||
| Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. | Q46032803 | ||
| Omalizumab therapy for bullous pemphigoid. | Q46085028 | ||
| Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. | Q46424938 | ||
| Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 | ||
| Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial | Q48509747 | ||
| A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis | Q48774760 | ||
| Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis | Q49046464 | ||
| Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps | Q49069941 | ||
| Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma | Q49152600 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 15-24 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Allergy, Asthma & Immunology Research | Q13429052 |
| P1476 | title | Personalized Medicine in Allergy | |
| P478 | volume | 9 |
| Q55334503 | A critical appraisal on AIT in childhood asthma. |
| Q64284796 | Altered Sphingolipid Metabolism Is Associated With Asthma Phenotype in House Dust Mite-Allergic Patients |
| Q41605623 | Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma |
| Q47377237 | Biomarkers: Delivering on the expectation of molecularly driven, quantitative health |
| Q63431936 | Engineering Precision Medicine |
| Q64085803 | Korean childhood asthma study (KAS): a prospective, observational cohort of Korean asthmatic children |
| Q39378515 | Molecular aspects of allergens in atopic dermatitis |
| Q53072682 | Perceptions of Severe Asthma and Asthma-COPD Overlap Syndrome Among Specialists: A Questionnaire Survey. |
| Q39201543 | Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? |
| Q57279736 | Serum Periostin Is Negatively Correlated With Exposure to Formaldehyde and Volatile Organic Compounds in Children |
| Q59806026 | Serum Periostin Levels: A Potential Serologic Marker for Toluene Diisocyanate-Induced Occupational Asthma |
| Q39189229 | Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations. |
| Q55513604 | Tolerogenic Dendritic Cells Reduce Airway Inflammation in a Model of Dust Mite Triggered Allergic Inflammation. |
Search more.